

Talvey

Oman · access guide

How to access Talvey from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Oman patient with relapsed or refractory multiple myeloma whose disease has progressed after multiple prior lines, including exposure to BCMA-directed therapies, may be evaluated by their haematologist for Talvey (talquetamab-tgvs). Talvey is FDA-approved, developed by Janssen (Johnson & Johnson), and is a GPRC5D×CD3 bispecific antibody. By targeting GPRC5D rather than BCMA, Talvey offers an alternative immunotherapy axis for patients whose myeloma has escaped BCMA-directed therapies or who need a non-BCMA option upfront. In Oman, Talvey is not yet broadly registered, which is why your haematologist may be navigating a named-patient import pathway on your behalf.

This guide explains the pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Talvey is administered subcutaneously on a step-up schedule to reduce cytokine release syndrome risk, small priming doses followed by a weekly or bi-weekly target dose. Step-up is typically conducted in an inpatient or closely monitored haematology unit; subsequent doses transition to outpatient dosing. Eligibility is based on prior line history, fitness for immune-engaging therapy, and access to a unit familiar with CRS, neurotoxicity, and GPRC5D-specific adverse-event patterns such as dysgeusia and dermatologic effects. Your haematologist will confirm eligibility and coordinate the step-up admission.

Is Talvey legally importable into Oman?

Yes, through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.

The named-patient mechanism allows a Oman-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody. For Talvey, a cold-chain biologic administered after a hospital-based step-up, most Oman tertiary haematology units already have the infrastructure.

How the pathway works, step by step

1. **Consultation with your treating haematologist.** Eligibility assessment including prior BCMA exposure where relevant, line history, and fitness for bispecific therapy.
2. **Haematology unit coordination.** The admitting haematology unit confirms step-up admission capacity and CRS/neurotoxicity monitoring protocols.
3. **DGPADC named-patient application.** Your physician or hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
5. **Cold-chain shipment.** The product ships with continuous temperature monitoring and chain-of-custody documentation.
6. **Arrival, step-up admission, and ongoing dosing.** The hospital pharmacy releases doses for the step-up admission and subsequent outpatient injections.

What documentation your physician needs

Your physician will typically need to provide:

- A clinical rationale letter confirming relapsed/refractory myeloma, line history (including prior BCMA exposure if applicable), and Talvey as the indicated treatment
- Verification of their Oman medical licence
- Identification of the admitting haematology unit and the CRS/neurotoxicity monitoring plan
- Patient identifier (anonymised reference where possible)
- Planned step-up schedule and transition to maintenance dosing

Reserve Meds provides a physician documentation kit that bundles the templates DGPADC reviewers expect to see, including the GPRC5D-specific adverse-event surveillance plan (dysgeusia, skin, nail changes).

Costs and timing

Talvey's US cash-pay drug-only reference price is driven by vial size and dosing frequency. Indicative 2026 cost for a 4-week maintenance supply sits in a broad range of roughly USD 38,000-46,000, with total course cost driven by duration on therapy. The initial step-up cycle typically includes inpatient monitoring costs locally. Cold-chain logistics, DGPADC documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing for the first step-up dose after cohort intake opens is 14-21 days from the moment a complete DGPADC application is submitted. Subsequent doses ship on a rolling basis against your dosing calendar.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

A culturally-aware note: Talvey commonly causes taste alteration and skin/nail changes. Families in the Gulf often prepare specific foods during illness as an expression of care; our concierge team shares an orientation brief on practical dietary and skin-care adjustments that can help patients tolerate therapy better.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Talvey specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and for DGPADC review.
- **Logistics.** Cold-chain, temperature-monitored shipment coordination.
- **Concierge case lead.** A named point of contact for your family and your physician through intake, step-up, and maintenance.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and the admitting unit.

Frequently asked

Is this legal in Oman? Yes, when executed through the DGPADC (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import is a routine mechanism across Oman haematology. See our trust and compliance page.

Why GPRC5D rather than BCMA? GPRC5D is a distinct target expressed on myeloma plasma cells. For patients who have already been exposed to BCMA-directed therapy (CAR-T or bispecifics) and whose disease has progressed, a non-BCMA target can restore a tumour-engagement axis. Your haematologist will explain sequencing.

How long is the inpatient step-up? The step-up admission length varies by centre and patient response. The Oman tertiary haematology units follow standing international protocols; your team will advise on expected length.

What about dysgeusia and skin effects? These are known features of the GPRC5D class and are typically manageable with supportive care. Your haematology team will guide you and your family.

Will private insurance cover this? Cash-pay is the default. Some Oman insurers consider named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com